Samsara Bio Capital, LLC Spring Works Therapeutics, Inc. Transaction History

Samsara Bio Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$18.36 - $60.07 $679,320 - $2.22 Million	-37,000 Reduced 62.5%	22,204 $547,000
Q1 2022 May 16, 2022	SELL	$48.97 - $65.46 $3.97 Million - $5.31 Million	-81,063 Reduced 57.79%	59,204 $3.34 Million
Q4 2021 Feb 14, 2022	SELL	$53.3 - $75.84 $1.58 Million - $2.24 Million	-29,585 Reduced 17.42%	140,267 $8.69 Million
Q1 2021 May 18, 2021	SELL	$65.1 - $93.59 $6.04 Million - $8.68 Million	-92,720 Reduced 35.31%	169,852 $12.5 Million
Q4 2020 Feb 17, 2021	SELL	$48.36 - $77.92 $6.55 Million - $10.6 Million	-135,445 Reduced 34.03%	262,572 $19 Million
Q3 2020 Nov 16, 2020	SELL	$36.14 - $51.99 $5.76 Million - $8.28 Million	-159,339 Reduced 28.59%	398,017 $19 Million
Q2 2020 Aug 14, 2020	SELL	$22.98 - $48.57 $1.56 Million - $3.3 Million	-67,925 Reduced 10.86%	557,356 $23.4 Million
Q1 2020 May 15, 2020	SELL	$20.44 - $41.21 $576,837 - $1.16 Million	-28,221 Reduced 4.32%	625,281 $16.9 Million
Q4 2019 Feb 18, 2020	SELL	$17.74 - $39.52 $409,793 - $912,912	-23,100 Reduced 3.41%	653,502 $25.2 Million
Q3 2019 Nov 14, 2019	BUY	$18.8 - $27.82 $12.7 Million - $18.8 Million	676,602 New	676,602 $14.7 Million

237

68.9M

144K

257K

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.22B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samsara Bio Capital, LLC with notifications on news.